Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Increased respiratory morbidity in individuals with interstitial lung abnormalities

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{9daf339f972a4c0f844a546c6cfe6d38,
title = "Increased respiratory morbidity in individuals with interstitial lung abnormalities",
abstract = "Background: Interstitial lung abnormalities (ILA) are common in participants of lung cancer screening trials and broad population-based cohorts. They are associated with increased mortality, but less is known about disease specific morbidity and healthcare utilisation in individuals with ILA. Methods: We included all participants from the screening arm of the Danish Lung Cancer Screening Trial with available baseline CT scan data (n = 1990) in this cohort study. The baseline scan was scored for the presence of ILA and patients were followed for up to 12 years. Data about all hospital admissions, primary healthcare visits and medicine prescriptions were collected from the Danish National Health Registries and used to determine the participants' disease specific morbidity and healthcare utilisation using Cox proportional hazards models. Results: The 332 (16.7{\%}) participants with ILA were more likely to be diagnosed with one of several respiratory diseases, including interstitial lung disease (HR: 4.9, 95{\%} CI: 1.8-13.3, p = 0.008), COPD (HR: 1.7, 95{\%} CI: 1.2-2.3, p = 0.01), pneumonia (HR: 2.0, 95{\%} CI: 1.4-2.7, p < 0.001), lung cancer (HR: 2.7, 95{\%} CI: 1.8-4.0, p < 0.001) and respiratory failure (HR: 1.8, 95{\%} CI: 1.1-3.0, p = 0.03) compared with participants without ILA. These findings were confirmed by increased hospital admission rates with these diagnoses and more frequent prescriptions for inhalation medicine and antibiotics in participants with ILA. Conclusions: Individuals with ILA are more likely to receive a diagnosis and treatment for several respiratory diseases, including interstitial lung disease, COPD, pneumonia, lung cancer and respiratory failure during long-term follow-up.",
keywords = "Clinical epidemiology, Imaging, Interstitial fibrosis, Lung Cancer",
author = "Nils Hoyer and Thomsen, {Laura H} and Wille, {Mathilde M W} and Torgny Wilcke and Asger Dirksen and Pedersen, {Jesper H} and Zaigham Saghir and Haseem Ashraf and Shaker, {Saher B}",
year = "2020",
month = "3",
day = "19",
doi = "10.1186/s12890-020-1107-0",
language = "English",
volume = "20",
pages = "67",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Increased respiratory morbidity in individuals with interstitial lung abnormalities

AU - Hoyer, Nils

AU - Thomsen, Laura H

AU - Wille, Mathilde M W

AU - Wilcke, Torgny

AU - Dirksen, Asger

AU - Pedersen, Jesper H

AU - Saghir, Zaigham

AU - Ashraf, Haseem

AU - Shaker, Saher B

PY - 2020/3/19

Y1 - 2020/3/19

N2 - Background: Interstitial lung abnormalities (ILA) are common in participants of lung cancer screening trials and broad population-based cohorts. They are associated with increased mortality, but less is known about disease specific morbidity and healthcare utilisation in individuals with ILA. Methods: We included all participants from the screening arm of the Danish Lung Cancer Screening Trial with available baseline CT scan data (n = 1990) in this cohort study. The baseline scan was scored for the presence of ILA and patients were followed for up to 12 years. Data about all hospital admissions, primary healthcare visits and medicine prescriptions were collected from the Danish National Health Registries and used to determine the participants' disease specific morbidity and healthcare utilisation using Cox proportional hazards models. Results: The 332 (16.7%) participants with ILA were more likely to be diagnosed with one of several respiratory diseases, including interstitial lung disease (HR: 4.9, 95% CI: 1.8-13.3, p = 0.008), COPD (HR: 1.7, 95% CI: 1.2-2.3, p = 0.01), pneumonia (HR: 2.0, 95% CI: 1.4-2.7, p < 0.001), lung cancer (HR: 2.7, 95% CI: 1.8-4.0, p < 0.001) and respiratory failure (HR: 1.8, 95% CI: 1.1-3.0, p = 0.03) compared with participants without ILA. These findings were confirmed by increased hospital admission rates with these diagnoses and more frequent prescriptions for inhalation medicine and antibiotics in participants with ILA. Conclusions: Individuals with ILA are more likely to receive a diagnosis and treatment for several respiratory diseases, including interstitial lung disease, COPD, pneumonia, lung cancer and respiratory failure during long-term follow-up.

AB - Background: Interstitial lung abnormalities (ILA) are common in participants of lung cancer screening trials and broad population-based cohorts. They are associated with increased mortality, but less is known about disease specific morbidity and healthcare utilisation in individuals with ILA. Methods: We included all participants from the screening arm of the Danish Lung Cancer Screening Trial with available baseline CT scan data (n = 1990) in this cohort study. The baseline scan was scored for the presence of ILA and patients were followed for up to 12 years. Data about all hospital admissions, primary healthcare visits and medicine prescriptions were collected from the Danish National Health Registries and used to determine the participants' disease specific morbidity and healthcare utilisation using Cox proportional hazards models. Results: The 332 (16.7%) participants with ILA were more likely to be diagnosed with one of several respiratory diseases, including interstitial lung disease (HR: 4.9, 95% CI: 1.8-13.3, p = 0.008), COPD (HR: 1.7, 95% CI: 1.2-2.3, p = 0.01), pneumonia (HR: 2.0, 95% CI: 1.4-2.7, p < 0.001), lung cancer (HR: 2.7, 95% CI: 1.8-4.0, p < 0.001) and respiratory failure (HR: 1.8, 95% CI: 1.1-3.0, p = 0.03) compared with participants without ILA. These findings were confirmed by increased hospital admission rates with these diagnoses and more frequent prescriptions for inhalation medicine and antibiotics in participants with ILA. Conclusions: Individuals with ILA are more likely to receive a diagnosis and treatment for several respiratory diseases, including interstitial lung disease, COPD, pneumonia, lung cancer and respiratory failure during long-term follow-up.

KW - Clinical epidemiology

KW - Imaging

KW - Interstitial fibrosis

KW - Lung Cancer

UR - http://www.scopus.com/inward/record.url?scp=85082060994&partnerID=8YFLogxK

U2 - 10.1186/s12890-020-1107-0

DO - 10.1186/s12890-020-1107-0

M3 - Journal article

VL - 20

SP - 67

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

IS - 1

M1 - 67

ER -

ID: 59579993